Scott Gleason was named Chief Financial Officer of Sera Prognostics, Inc., effective August 31, 2026. As of November 6, 2026, Sera Prognostics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 1, 2026 to August 19, 2026, naming 1 appointment and 1 departure (Form 8-K, August 19, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Sera Prognostics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Scott Gleason · Role: Chief Financial Officer · Effective: 2026-08-31 · 8-K, 2026-08-19
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-30
- · In / out: Out · Person: Jeffrey T. Elliott · Role: Director · Effective: 2026-06-04 · 8-K, 2026-06-01
Sera Prognostics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-01 to 2026-08-19. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Sera Prognostics, Inc. files it.
Also on the record for Sera Prognostics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 15, 2026 | Stake report, Schedule 13G/A, by Aberdeen Group plc | 7.21% of the class | 5%+ stakes | Source |
| May 1, 2026 | Stake report, Schedule 13G/A, by Whetstone Capital Advisors, LLC | 8.6% of the class | 5%+ stakes | Source |
| January 16, 2026 | Stake report, Schedule 13G/A, by Whetstone Capital Advisors, LLC | 9.2% of the class | 5%+ stakes | Source |
| September 8, 2025 | Stake report, Schedule 13G, by Whetstone Capital Advisors, LLC | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | — | 5%+ stakes | Source |
| August 5, 2025 | Stake report, Schedule 13G, by Aberdeen Group plc | 6.07% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Sera Prognostics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Sera Prognostics, Inc. and the records around it.
Sera Prognostics, Inc. elsewhere on the record
Companies that share a holder
- Whetstone Capital Advisors, LLC also filed stake reports on 3 other companies: Health Catalyst, Inc. (Jun 2026), Open Lending Corp (May 2026)
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Watch Sera Prognostics, Inc.
Get an email when Sera Prognostics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Sera Prognostics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Sera Prognostics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Sera Prognostics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-19 | In | Chief Financial Officer | 2026-08-31 | 8-K, 2026-08-19 | |
| 2026-06-30 | Reported | not named in the filing | 8-K, 2026-06-30 | ||
| 2026-06-01 | Out | Director | 2026-06-04 | 8-K, 2026-06-01 |
Who leads Sera Prognostics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Scott Gleason, appointed, effective 2026-08-31 (filed 2026-08-19).
- Director: Jeffrey T. Elliott, departure reported, effective 2026-06-04 (filed 2026-06-01). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Sera Prognostics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Sera Prognostics, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Sera Prognostics, Inc.Every change, in the filing's words
Appointed: Scott Gleason, Chief Financial Officer, effective 2026-08-31
Appointment of New Chief Financial Officer and Treasurer effective August 31, 2026 On August 14, 2026, the Board of Directors appointed Scott Gleason to serve as the next Chief Financial Officer and Treasurer of Sera Prognostics, Inc. (the "Company"), effective August 31, 2026, pursuant to the planned transition described below.
- In the Company press release for the announcement, Sera's Chief Executive Officer and President, Zhenya Lindgardt remarked: "Scott brings a unique combination of CFO experience, investor relations expertise, and strategic leadership that will be an important asset as we strengthen commercial execution and support our business priorities." Biographical information about Mr. Gleason is as follows: Scott Gleason, 47 years of age, is a diagnostics, life sciences, and healthcare executive with approximately 25 years of experience in finance, investor relations, corporate strategy, corporate communications, and equity research.
- Prior to joining the Company, he served as Vice President, Investor Relations and Treasury, of Neogen Corporation, an international food safety company, from December 2025 to July 2026, and he served as Chief Financial Officer of NX Prenatal, Inc., a molecular diagnostics company focused on women's health, from February 2024 to March 2026.
- Mr. Gleason also served as Chief Financial Officer of LarmorBio, Inc., a Boston-based life sciences and clinical diagnostics startup, from November 2024 to December 2025.
Reported
On June 25, 2026, upon the recommendation of the Nominating and Governance Committee of the Board of Directors (the "Board") of Sera Prognostics, Inc. (the "Company"), and pursuant to the Amended and Restated Bylaws of the Company, the Board appointed, effective as of July 1, 2026, Mark Capone to serve as a Class II director, with an initial term expiring at the Company's 2029 annual meeting of stockholders.
- In connection with and effective as of his appointment to the Board, Mr. Capone was also appointed to the Compensation Committee of the Board (the "Compensation Committee").
- Mark Capone is an accomplished healthcare executive with more than 40 years of experience in molecular diagnostics, genetics, biotechnology, medical devices and pharmaceuticals.
- Since January 2024, Mr. Capone has served as a director and member of the audit committee of Mesa Laboratories, Inc. (Nasdaq: MLAB) ("Mesa") and was also appointed as a member of Mesa's compensation committee in August 2025.
- Since March 2020, Mr. Capone has served as the CEO of Precision Medicine Advisors, LLC, a consulting company advising biopharmaceutical organizations.
- Previously, Mr. Capone served for five years as CEO of Myriad Genetics, a pioneering precision medicine company.
- During his 17-year career at Myriad, he transformed the company from $14M revenue, 150 employees, and one product to a global leader in precision medicine with $850M in revenue, 3,000 employees, and 11 products, four of which were obtained through acquisitions that deployed more than $1B in capital.
- Prior to joining Myriad Genetics, Mr. Capone served in a variety of roles with Eli Lilly and Company, including as Sales Director, Plant Manager, R&D Team Leader, and Biochemical Engineer.
Departing: Jeffrey T. Elliott, Director, effective 2026-06-04
On May 26, 2026, Jeffrey T. Elliott, a member of the Board of Directors (the "Board") of Sera Prognostics, Inc. (the "Company"), notified the Company of his decision to resign from the Board effective as of June 4, 2026, the date of the Company's Annual Stockholders Meeting ("Annual Meeting").
- Mr. Elliott's resignation was not as a result of any disagreement between Mr. Elliott and the Company on any matter relating to the Company's operations, policies or practices.
- Mr. Elliott's term as a director was scheduled to expire at the Annual Meeting.
- As a result of this resignation, Mr. Elliott is no longer a director nominee for re-election at the Annual Meeting.
- In connection with Mr. Elliott's resignation, the Company's board of directors (the "Board") decreased its size to seven directors.
- Separately, as part of its ongoing focus on strong corporate governance and leadership continuity, the Company is in advanced discussions with highly qualified candidates to join the Board and expects to announce an appointment in the near term.
Tools for this story
Each opens in a new tab, filled in for Sera Prognostics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.